Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cell Therapeutics’ Tosedostat Gets Back On Track

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA lifts clinical hold on first-in-class aminopeptidase inhibitor tosedostat, in investigator-sponsored Phase II trials for blood-related cancers as part of the company’s economic development strategy.


Related Content

CTI’s Pixuvri Flops Again At British NICE, As Discount Fails To Impress
Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review
Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts